Details

Autor(en) / Beteiligte

• Cui, Tai-gen
• Hou, Fan-fan
• Ni, Zhao-hui
• Chen, Xiang-mei
• Zhang, Feng-shan
• Zhu, Tong-ying
• Zhao, Xue-zhi
• Bao, Chun-de
• Zhao, Ming-hui
• Wang, Guo-bao
• Qian, Jia-qi
• Cai, Guang-yan
• Li, Ying-nan
• Lu, Fu-ming
• Mei, Chang-lin
• Zou, Wan-zhong
• Wang, Hai-yan

Titel

Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial

Ist Teil von

• Chung-hua nei kʿo tsa chih, 2005-09, Vol.44 (9), p.672

Ort / Verlag

China

Erscheinungsjahr

2005

Quelle

MEDLINE

Beschreibungen/Notizen

• Leflunomide (LEF) is a selective inhibitor of de novo pyrimidine synthesis, currently used in the treatment of rheumatoid arthritis. To evaluate the efficacy and safety of LEF in the treatment of proliferative lupus nephritis, a prospective multi-center controlled clinical trial was conducted. Patients with biopsy-confirmed proliferative lupus nephritis were recruited. Patients of recent onset who had not used any immunosuppressive drug were given either oral LEF (group A) or IV cyclophosphamide (group B); relapsed patients who had received immunosuppressive therapy 3 months before were given LEF (group C). Efficacy and safety were evaluated at 6 months after treatment. Total 51 patients were enrolled, 4 patients withdrew due to adverse events. For those initial treated patients, total response rate were 80% in group A and 75% in group B, complete remission rate were 40% and 25% respectively, not statistically different. Renal parameters (proteinuria, serum albumin and serum creatinine) and systemic lupus ery